Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;59(8):5029-31.
doi: 10.1128/AAC.00830-15. Epub 2015 May 26.

Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City

Amabel Lapuebla  1 , Marie Abdallah  1 , Olawole Olafisoye  1 , Christopher Cortes  2 , Carl Urban  2 , David Landman  1 , John Quale  3
Affiliations

Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City

Amabel Lapuebla et al. Antimicrob Agents Chemother. 2015 Aug.

Abstract

Imipenem with relebactam was active against Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp., including K. pneumoniae carbapenemase (KPC)-producing isolates. Loss of OmpK36 in KPC-producing K. pneumoniae isolates affected the susceptibility of this combination. Enhanced activity was evident against Pseudomonas aeruginosa, including isolates with depressed oprD and increased ampC expression. However, the addition of relebactam to imipenem did not provide added benefit against Acinetobacter baumannii. The combination of imipenem with relebactam demonstrated activity against KPC-producing Enterobacteriaceae and multidrug-resistant P. aeruginosa.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Patel G, Bonomo RA. 2013. “Stormy waters ahead”: global emergence of carbapenemases. Front Microbiol 4:48. doi:10.3389/fmicb.2013.00048. - DOI - PMC - PubMed
    1. Nordmann P, Cuzon G, Nass T. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 9:228–236. doi:10.1016/S1473-3099(09)70054-4. - DOI - PubMed
    1. Drawz SM, Papp-Wallace KM, Bonomo RA. 2014. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58:1835–1846. doi:10.1128/AAC.00826-13. - DOI - PMC - PubMed
    1. Toussaint KA, Gallagher JC. 2015. β-Lactam/β-lactamase inhibitor combinations: from then to now. Ann Pharmacother 49:86–98. doi:10.1177/1060028014556652. - DOI - PubMed
    1. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. Approved standard M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.

Publication types

MeSH terms

LinkOut - more resources